Cite
HARVARD Citation
Quach, H. et al. (2017). Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. British journal of haematology. pp. 441-448. [Online].